{"protocolSection":{"identificationModule":{"nctId":"NCT03000569","orgStudyIdInfo":{"id":"217-PRK-201"},"organization":{"fullName":"Biogen","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease","officialTitle":"A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-11-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-09-11","type":"ACTUAL"},"completionDateStruct":{"date":"2017-09-11","type":"ACTUAL"},"studyFirstSubmitDate":"2016-11-28","studyFirstSubmitQcDate":"2016-12-19","studyFirstPostDateStruct":{"date":"2016-12-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-09-17","resultsFirstSubmitQcDate":"2020-10-29","resultsFirstPostDateStruct":{"date":"2020-11-23","type":"ACTUAL"},"dispFirstSubmitDate":"2018-09-17","dispFirstSubmitQcDate":"2018-10-09","dispFirstPostDateStruct":{"date":"2018-10-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-27","lastUpdatePostDateStruct":{"date":"2023-11-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biogen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29 participants with moderate to severe Parkinson's Disease.","detailedDescription":"Part A of the study is an open-label design with dosing of Levodopa for 3 days followed by SAGE-217 for 4 days.\n\nPart B of the study is an open-label design with evening dosing of SAGE-217 for 7 days as an adjunct to antiparkinsonian agent(s).\n\nThis study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen."},"conditionsModule":{"conditions":["Parkinson Disease"],"keywords":["Parkinson's"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":29,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","type":"EXPERIMENTAL","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.","interventionNames":["Drug: SAGE-217","Drug: Levodopa"]},{"label":"Part B: Antiparkinsonian Agent(s) + SAGE-217","type":"EXPERIMENTAL","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.","interventionNames":["Drug: SAGE-217","Drug: Antiparkinsonian Agent(s)"]}],"interventions":[{"type":"DRUG","name":"SAGE-217","armGroupLabels":["Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","Part B: Antiparkinsonian Agent(s) + SAGE-217"]},{"type":"DRUG","name":"Levodopa","description":"Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).","armGroupLabels":["Part A: Antiparkinsonian Agent(s) Followed by SAGE-217"]},{"type":"DRUG","name":"Antiparkinsonian Agent(s)","description":"Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.","armGroupLabels":["Part B: Antiparkinsonian Agent(s) + SAGE-217"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"Percentage of Participants With TEAEs, Graded by Severity - Part A","description":"Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with an inability to perform normal activities). The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"Change From Baseline (CFB) in Basophils - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Basophils to Leukocytes Ratio [Percentage (%)] - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as International System (SI) unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Eosinophils - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Eosinophils to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Erythrocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Hematocrit - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Hemoglobin - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Leukocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Lymphocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Lymphocytes to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Monocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Monocytes to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Neutrophils- Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Neutrophils to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Platelets - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Reticulocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Reticulocytes to Erythrocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Activated Partial Thromboplastin Time - Part A","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Prothrombin International Normalized Ratio - Part A","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Prothrombin Time - Part A","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Alanine Aminotransferase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Albumin - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Alkaline Phosphatase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aspartate Aminotransferase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Bicarbonate - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Bilirubin - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Calcium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Chloride - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Creatinine - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Lipase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Magnesium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Phosphate - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Potassium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Protein - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Sodium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Urate - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Urea Nitrogen - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Specific Gravity - Part A","description":"Urinalysis measures included specific gravity and potential of hydrogen (pH). Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in pH - Part A","description":"Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Temperature - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Heart Rate - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Respiratory Rate - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Supine Systolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Standing Systolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Supine Diastolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Standing Diastolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Pulse Oximetry- Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Electrocardiogram (ECG) Mean Heart Rate - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate PR Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate RR Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate QT Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate QRS Duration - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate QTcF Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Stanford Sleepiness Scale (SSS) Score - Part A","description":"The SSS was a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of one to seven, where the lowest score of 'one' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of 'seven' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. A negative change from baseline indicated less sleepiness. A positive change from baseline indicated more sleepiness. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item - Part A","description":"The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included \"yes\" or \"no\"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part A of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II/III Score - Part B","description":"The modified MDS-UPDRS included 4 scales, with various subscales. Each item was rated from 0 (normal) to 4 (severe). The scales were Part I: nonmotor experiences of daily living (13 items); Part II: motor experiences of daily living (13 items); Part III: motor examination (33 scores based on 18 items \\[several with right, left or other body distribution scores\\]); and Part IV: motor complications (6 items). The Part II/III tremor score was calculated as the sum of 5 individual tremor item scores from Part II and Part III. The total score range for Part II/III is 0 to 44. Lower scores represent less symptom severity and higher scores represent more symptom severity. Baseline is the last measurement taken before the first dose of study drug. A negative change from baseline indicates an improvement in symptom severity. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14"}],"secondaryOutcomes":[{"measure":"MDS-UPDRS Part III Total Score - Part A","description":"Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores indicate less symptom severity. The analysis was performed in participants included in Part A of the study.","timeFrame":"Days 1 to 7 (2, 4, 8, and 12 hours postdose), Day 8 and Day 14"},{"measure":"CFB in the MDS-UPDRS Part III Total Score - Part B","description":"Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of the individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores represent less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14"},{"measure":"CFB in the MDS-UPDRS Part I Total Score - Part B","description":"Part I of the MDS-UPDRS assessed 13 nonmotor experiences of daily living categories. Part I total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Baseline, Day 7 (12 hours postdose), Day 14"},{"measure":"CFB in the MDS-UPDRS Part II Total Score - Part B","description":"Part II of the MDS-UPDRS assessed 13 categories of motor experiences of daily living: speech, salivation and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor, getting out of bed, car, or deep chair, walking and balance, and freezing. The Part II total score was calculated as the sum of the individual item scores from these categories. The total score range for Part II is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14"},{"measure":"CFB in the MDS-UPDRS Part I-IV Total Score - Part B","description":"The MDS-UPDRS assesses nonmotor experiences, motor experiences, motor skills, and motor complication categories. The MDS-UPDRS Part I-IV total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I-IV is 0 to 260. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Baseline, Day 7 (12 hours postdose), Day 14"},{"measure":"Percentage of Participants With TEAEs - Part B","description":"An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"Percentage of Participants With TEAEs, Graded by Severity - Part B","description":"Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with inability to perform normal activities). The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Basophils - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Basophils to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Eosinophils - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Eosinophils to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Erythrocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Hematocrit - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Hemoglobin - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Leukocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Lymphocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Lymphocytes to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Monocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Monocytes to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Neutrophils - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Neutrophils to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Platelets - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Reticulocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Reticulocytes to Erythrocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Activated Partial Thromboplastin Time - Part B","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Prothrombin International Normalized Ratio - Part B","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Prothrombin Time - Part B","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Alanine Aminotransferase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Albumin - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Alkaline Phosphatase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aspartate Aminotransferase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Bicarbonate - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Bilirubin - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Calcium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Chloride - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Creatinine - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Lipase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Magnesium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Phosphate - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Potassium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Protein - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Sodium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Urate - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Urea Nitrogen - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Specific Gravity - Part B","description":"Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in pH - Part B","description":"Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Temperature - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Heart Rate - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Respiratory Rate - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Supine Systolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Standing Systolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Supine Diastolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Standing Diastolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Pulse Oximetry - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in ECG Mean Heart Rate - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate PR Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate RR Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate QT Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate QRS Duration - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"CFB in Aggregate QTcF Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"},{"measure":"Percentage of Participants With a Response of 'Yes' to Any C-SSRS Suicidal Ideation or Suicidal Behavior Item - Part B","description":"The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included \"yes\" or \"no\"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part B of the study.","timeFrame":"Day 1 to Day 14"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has a diagnosis of idiopathic Parkinson's Disease (Hoehn and Yahr Stage 2 or Stage 3) with a duration of less than 7 years prior to screening \\[Part A\\]\n* Participant has a diagnosis of idiopathic Parkinson's Disease (Hoehn and Yahr Stage 1-4, assessed during the \"on\" period) \\[Part B\\]\n* Participant is on a stable dose (at least 1 month prior to baseline visit) of an antiparkinsonian agent and is willing to remain on this dose for the duration of the study\n\nExclusion Criteria:\n\n* Participant has early (Hoehn and Yahr Stage 1) or advanced (Hoehn and Yahr Stage 4 or Stage 5) Parkinson's Disease \\[Part A\\]\n* Participant has advanced (Hoehn and Yahr Stage 5) Parkinson's Disease \\[Part B\\]\n* Participant with presence of drug-induced parkinsonism, metabolic identified neurogenetic disorders, encephalitis, or other atypical Parkinsonian syndromes\n* Participant with medical history of electroconvulsive therapy or stereotaxic brain surgery for Parkinson's Disease\n* Participant with medical history of suicide attempt within 2 years of screening or current suicidal ideation\n* Participant with medical history of impulse control disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Sage Investigational Site","city":"Panorama City","state":"California","zip":"91402","country":"United States","geoPoint":{"lat":34.22473,"lon":-118.44981}},{"facility":"Sage Investigational Site","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Sage Investigational Site","city":"Miami","state":"Florida","zip":"33135","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Sage Investigational Site","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Sage Investigational Site","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Sage Investigational Site","city":"Winter Park","state":"Florida","zip":"32789","country":"United States","geoPoint":{"lat":28.6,"lon":-81.33924}},{"facility":"Sage Investigational Site","city":"Atlanta","state":"Georgia","zip":"30331","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Sage Investigational Site","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"Sage Investigational Site","city":"Berlin","state":"New Jersey","zip":"08009","country":"United States","geoPoint":{"lat":39.79123,"lon":-74.92905}},{"facility":"Sage Investigational Site","city":"Houston","state":"Texas","zip":"77058","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Sage Investigational Site","city":"Orem","state":"Utah","zip":"84058","country":"United States","geoPoint":{"lat":40.2969,"lon":-111.69465}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"http://www.sagerx.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Participants were enrolled at 9 sites in the United States and took part in the study which ran from 30 November 2016 to 11 September 2017.","groups":[{"id":"FG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."},{"id":"FG001","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The safety population included all participants who were administered study drug \\[SAGE-217 or levodopa (Part A); or SAGE-217 or antiparkinsonian agent(s) (Part B)\\].","groups":[{"id":"BG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."},{"id":"BG001","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"29"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.9","spread":"6.59"},{"groupId":"BG001","value":"65.1","spread":"7.76"},{"groupId":"BG002","value":"64.5","spread":"7.17"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"20"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"26"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Overall number of participants analyzed = Number of participants in the safety population that remained in the study during each period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Day 1 to Day 3","description":"Participants received levodopa as antiparkinsonian agents at the normally prescribed dosing schedule, orally for Days 1 to 3."},{"id":"OG001","title":"Part A: SAGE-217 Day 4 to Day 7","description":"Participants received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. If the initial dose was not tolerated, doses could be reduced to 10 or 20 mg per day."},{"id":"OG002","title":"Part A: Follow-up","description":"Participants resumed levodopa as antiparkinsonian agents at the normally prescribed dosing schedule for Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"13.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With TEAEs, Graded by Severity - Part A","description":"Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with an inability to perform normal activities). The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Overall number of participants analyzed = Number of participants in the safety population that remained in the study during each period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Day 1 to Day 3","description":"Participants received levodopa as antiparkinsonian agents at the normally prescribed dosing schedule, orally for Days 1 to 3."},{"id":"OG001","title":"Part A: SAGE-217 Day 4 to Day 7","description":"Participants received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. If the initial dose was not tolerated, doses could be reduced to 10 or 20 mg per day."},{"id":"OG002","title":"Part A: Follow-up","description":"Participants resumed levodopa as antiparkinsonian agents at the normally prescribed dosing schedule for Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"15"}]}],"classes":[{"title":"Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6.7"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"85.7"},{"groupId":"OG002","value":"6.7"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"14.3"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline (CFB) in Basophils - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells per liter (10^9 cells/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.051"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.043"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.036"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.038"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.041"}]}]}]},{"type":"PRIMARY","title":"CFB in Basophils to Leukocytes Ratio [Percentage (%)] - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as International System (SI) unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.41"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.66"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.61"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.41"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.35"}]}]}]},{"type":"PRIMARY","title":"CFB in Eosinophils - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.098"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.083"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.051"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.073"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.053"}]}]}]},{"type":"PRIMARY","title":"CFB in Eosinophils to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.58"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.59"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.83"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.82"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.11"}]}]}]},{"type":"PRIMARY","title":"CFB in Erythrocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^12 cells per liter (10^12 cells/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.63","spread":"0.475"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.266"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.224"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.265"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.226"}]}]}]},{"type":"PRIMARY","title":"CFB in Hematocrit - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"liters per liter (L/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.434","spread":"0.0444"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":"0.0264"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":"0.0247"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.002","spread":"0.0285"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.013","spread":"0.0222"}]}]}]},{"type":"PRIMARY","title":"CFB in Hemoglobin - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"grams per liter (g/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142.0","spread":"13.87"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"7.55"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"7.25"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"8.14"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"5.82"}]}]}]},{"type":"PRIMARY","title":"CFB in Leukocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.04","spread":"1.139"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"1.085"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.536"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.874"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.941"}]}]}]},{"type":"PRIMARY","title":"CFB in Lymphocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":"0.318"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.289"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.352"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.286"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.183"}]}]}]},{"type":"PRIMARY","title":"CFB in Lymphocytes to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":"4.68"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"4.72"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"5.55"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"4.87"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"4.22"}]}]}]},{"type":"PRIMARY","title":"CFB in Monocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.112"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.125"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.076"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.101"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.064"}]}]}]},{"type":"PRIMARY","title":"CFB in Monocytes to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"1.06"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.48"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.45"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.33"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.22"}]}]}]},{"type":"PRIMARY","title":"CFB in Neutrophils- Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","spread":"0.861"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.848"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.599"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.680"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.861"}]}]}]},{"type":"PRIMARY","title":"CFB in Neutrophils to Leukocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":"4.26"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"4.94"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"5.58"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"4.86"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"4.64"}]}]}]},{"type":"PRIMARY","title":"CFB in Platelets - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"218.9","spread":"62.00"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"27.07"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"33.01"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"21.29"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"36.42"}]}]}]},{"type":"PRIMARY","title":"CFB in Reticulocytes - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":"20.36"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"17.87"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"19.21"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"20.18"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"14.10"}]}]}]},{"type":"PRIMARY","title":"CFB in Reticulocytes to Erythrocytes Ratio (%) - Part A","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"0.442"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.349"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.409"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.424"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.315"}]}]}]},{"type":"PRIMARY","title":"CFB in Activated Partial Thromboplastin Time - Part A","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"seconds (sec)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.80","lowerLimit":"22.9","upperLimit":"27.4"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","lowerLimit":"-1.5","upperLimit":"4.0"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","lowerLimit":"-4.8","upperLimit":"2.4"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","lowerLimit":"-1.6","upperLimit":"1.4"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","lowerLimit":"-2.1","upperLimit":"4.7"}]}]}]},{"type":"PRIMARY","title":"CFB in Prothrombin International Normalized Ratio - Part A","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"0.065"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.108"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.065"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.243"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.155"}]}]}]},{"type":"PRIMARY","title":"CFB in Prothrombin Time - Part A","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.70","lowerLimit":"10.2","upperLimit":"12.4"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"-0.6","upperLimit":"2.2"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"-1.2","upperLimit":"0.4"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","lowerLimit":"-0.7","upperLimit":"7.5"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","lowerLimit":"-1.2","upperLimit":"4.7"}]}]}]},{"type":"PRIMARY","title":"CFB in Alanine Aminotransferase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units per liter (U/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"8.12"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"11.61"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":"11.87"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"13.64"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"9.24"}]}]}]},{"type":"PRIMARY","title":"CFB in Albumin - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":"1.70"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.81"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.59"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.21"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.35"}]}]}]},{"type":"PRIMARY","title":"CFB in Alkaline Phosphatase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.6","spread":"14.17"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"9.34"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"4.52"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"4.78"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"8.06"}]}]}]},{"type":"PRIMARY","title":"CFB in Aspartate Aminotransferase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"7.24"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"6.15"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"4.93"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"5.25"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"5.16"}]}]}]},{"type":"PRIMARY","title":"CFB in Bicarbonate - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimoles per liter (mmol/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":"2.50"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.27"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.23"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.41"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"2.26"}]}]}]},{"type":"PRIMARY","title":"CFB in Bilirubin - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micromoles per liter (umol/L)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.082","spread":"3.8041"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.029","spread":"3.4758"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.949","spread":"3.8554"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.545","spread":"3.5965"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.543","spread":"3.7159"}]}]}]},{"type":"PRIMARY","title":"CFB in Calcium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.342","spread":"0.0588"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.030","spread":"0.0734"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.007","spread":"0.0779"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.014","spread":"0.0711"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.015","spread":"0.0842"}]}]}]},{"type":"PRIMARY","title":"CFB in Chloride - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.1","spread":"2.33"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.91"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.30"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.41"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.83"}]}]}]},{"type":"PRIMARY","title":"CFB in Creatinine - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.254","spread":"17.7960"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.399","spread":"8.6574"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.104","spread":"9.4424"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.420","spread":"10.9866"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.118","spread":"4.6761"}]}]}]},{"type":"PRIMARY","title":"CFB in Lipase - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":"10.16"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"22.15"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"77.58"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":"222.02"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"7.67"}]}]}]},{"type":"PRIMARY","title":"CFB in Magnesium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.861","spread":"0.0686"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.012","spread":"0.0409"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.0457"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.015","spread":"0.0617"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.0618"}]}]}]},{"type":"PRIMARY","title":"CFB in Phosphate - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.098","spread":"0.1189"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":"0.1413"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":"0.1645"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":"0.1513"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.034","spread":"0.1698"}]}]}]},{"type":"PRIMARY","title":"CFB in Potassium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.53","spread":"0.326"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.323"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.309"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.350"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.446"}]}]}]},{"type":"PRIMARY","title":"CFB in Protein - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":"3.07"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"4.12"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"3.86"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"3.65"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"4.33"}]}]}]},{"type":"PRIMARY","title":"CFB in Sodium - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"140.0","spread":"1.73"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"2.15"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.86"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"2.20"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.85"}]}]}]},{"type":"PRIMARY","title":"CFB in Urate - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.337","spread":"0.1000"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.005","spread":"0.0713"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":"0.0804"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":"0.0394"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.014","spread":"0.0649"}]}]}]},{"type":"PRIMARY","title":"CFB in Urea Nitrogen - Part A","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.831","spread":"1.3672"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.587","spread":"1.4925"}]}]},{"title":"CFB at Day 6 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.816","spread":"1.4715"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.663","spread":"1.5521"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.048","spread":"1.3484"}]}]}]},{"type":"PRIMARY","title":"CFB in Specific Gravity - Part A","description":"Urinalysis measures included specific gravity and potential of hydrogen (pH). Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.018","spread":"0.0049"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.001","spread":"0.0062"}]}]},{"title":"CFB at Day 7 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.0039"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"0.0059"}]}]}]},{"type":"PRIMARY","title":"CFB in pH - Part A","description":"Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pH","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.87","spread":"0.915"}]}]},{"title":"CFB at Day 4 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.973"}]}]},{"title":"CFB at Day 7 (SAGE-217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.881"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.884"}]}]}]},{"type":"PRIMARY","title":"CFB in Temperature - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"degrees Celsius (degrees C)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.61","spread":"0.228"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.180"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.205"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.236"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.227"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.285"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.235"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.412"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.319"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.296"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.346"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.316"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.348"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.323"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.279"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.274"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.283"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.380"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.380"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.365"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.409"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.305"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.277"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.272"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.331"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.363"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.276"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.422"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.372"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.176"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.208"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.175"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.387"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.236"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.236"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.230"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.336"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.333"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.185"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.233"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.187"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.287"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.360"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.272"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.449"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.310"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.421"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.400"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.273"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.383"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.359"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.306"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.322"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.322"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.358"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.260"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.329"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.697"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.434"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.434"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.302"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.282"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.407"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.310"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.332"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.252"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.208"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.145"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.235"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.363"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.224"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.301"}]}]}]},{"type":"PRIMARY","title":"CFB in Heart Rate - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats per minute (beats/min)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.6","spread":"11.83"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"5.87"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"6.76"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"5.87"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"6.63"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"7.75"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"7.55"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"6.86"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"7.18"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"5.03"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"6.80"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"7.37"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"8.10"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"10.71"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"5.23"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"7.08"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdos","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"7.81"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"8.38"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"7.29"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"7.29"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"9.29"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"6.67"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"9.46"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"7.20"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"6.30"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"7.33"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"5.43"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"9.72"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"8.63"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"7.08"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"5.21"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"6.43"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"8.97"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"10.38"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"6.27"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"8.72"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"7.97"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"9.70"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"6.64"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"7.37"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"8.25"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"6.99"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"9.06"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"8.18"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"11.03"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"11.24"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"9.50"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"9.51"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"7.98"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"9.34"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"7.58"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"6.53"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"7.86"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"7.51"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"10.09"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"10.07"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"11.00"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"10.87"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"9.51"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"10.87"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"11.06"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"8.29"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"6.49"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"12.50"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"7.77"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"8.46"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"4.66"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"9.82"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"9.27"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"7.93"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"6.52"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"8.29"}]}]}]},{"type":"PRIMARY","title":"CFB in Respiratory Rate - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"breaths per minute (breaths/min)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":"1.92"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.46"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.92"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.69"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.93"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.69"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"2.08"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.99"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.83"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.49"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.59"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.83"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.48"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.57"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.70"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.14"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.32"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.61"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.92"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.62"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.99"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.65"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.03"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.13"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.11"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.87"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.26"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.65"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.93"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"2.74"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.59"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.69"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.79"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.39"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.66"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.21"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.68"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.86"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.70"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.02"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.59"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.20"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.34"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.77"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.86"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.27"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.92"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.95"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.95"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.05"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.38"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.65"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.38"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.18"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.79"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.21"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.92"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.82"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.10"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.31"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.36"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.27"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.51"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.49"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.66"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.65"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.65"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.03"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.31"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"2.61"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.29"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.83"}]}]}]},{"type":"PRIMARY","title":"CFB in Supine Systolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeters of mercury (mmHg)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124.5","spread":"11.61"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"10.81"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"11.49"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"10.37"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"9.44"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"9.63"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"13.32"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"13.21"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"12.51"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"11.99"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"11.14"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"11.59"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"9.99"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"10.86"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"10.43"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"10.95"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"15.35"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"8.00"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"9.53"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"10.40"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"8.61"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"10.30"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"14.70"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"12.69"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"14.12"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"12.51"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"12.75"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"13.30"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"16.21"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"10.73"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"10.17"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"9.75"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"10.80"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"15.97"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"8.84"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"10.46"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"10.94"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"9.60"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"14.15"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"10.83"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"11.43"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"9.68"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"11.67"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"10.14"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"9.23"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"11.14"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"10.15"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"11.68"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"15.46"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"14.19"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"11.67"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"11.95"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"13.03"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"15.47"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"13.00"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"10.23"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"12.46"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"12.41"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"10.39"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"13.45"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"19.64"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"12.93"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"18.93"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"13.22"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"17.35"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"14.81"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"10.38"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"13.23"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"14.07"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"18.75"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"7.79"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"9.50"}]}]}]},{"type":"PRIMARY","title":"CFB in Standing Systolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124.1","spread":"12.38"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"9.98"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"10.00"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"11.45"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"11.78"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"13.34"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"10.22"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"17.85"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"10.18"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"9.51"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"11.09"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"10.57"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"11.56"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"9.86"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"10.12"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"8.50"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"10.20"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"16.97"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"11.08"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"10.14"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"7.84"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"8.17"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"11.83"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"13.07"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"13.13"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"9.35"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"10.83"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"14.56"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"15.65"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"11.98"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"13.32"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"14.74"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"10.60"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"11.77"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"10.04"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"8.50"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"9.16"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"12.72"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"10.09"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"10.07"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"9.61"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"12.60"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"10.52"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"14.81"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"9.82"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"12.05"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"10.16"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"12.51"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"17.97"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"15.37"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"12.00"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"10.89"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"9.34"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"10.36"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"8.55"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"9.45"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"12.79"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"12.13"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"13.57"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"19.21"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"12.25"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"13.06"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"13.19"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"9.27"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"13.96"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"13.65"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"10.80"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"14.54"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"13.23"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"11.95"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"9.90"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"13.14"}]}]}]},{"type":"PRIMARY","title":"CFB in Supine Diastolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":"7.19"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"6.02"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"5.92"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"6.66"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"5.26"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"9.91"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"9.04"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"7.89"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"8.94"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"10.34"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"7.10"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"9.49"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"9.90"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"11.37"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"7.78"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"10.09"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"10.47"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"7.57"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"8.08"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"7.13"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"7.29"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"8.51"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"8.11"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"9.77"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"13.63"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"8.77"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"9.90"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"8.32"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"7.80"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"8.69"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"7.82"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"6.72"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"6.48"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"8.19"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"8.01"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"8.75"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"7.08"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"6.93"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"8.84"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"7.05"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"8.43"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"7.72"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"6.17"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"6.62"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"6.93"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"8.22"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"7.00"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"9.17"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"7.84"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"10.02"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"7.59"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"9.72"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"9.31"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"8.99"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"11.37"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"8.09"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"8.06"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"9.17"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"7.71"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"10.30"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"6.75"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"7.79"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"9.61"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"10.46"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"9.40"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"8.58"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"10.02"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"8.58"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"10.65"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"9.66"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"8.05"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"7.22"}]}]}]},{"type":"PRIMARY","title":"CFB in Standing Diastolic Blood Pressure - Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":"10.57"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"8.71"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"7.26"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"7.92"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"5.57"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"10.54"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"7.16"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"7.04"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"7.65"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"7.19"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"8.41"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"7.89"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"12.25"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"8.53"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"10.08"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"12.55"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"10.91"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"6.80"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"5.99"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"5.34"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"7.82"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"9.44"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"6.98"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"12.74"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"11.23"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"9.94"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"11.90"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"7.43"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"9.57"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"10.98"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"9.11"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"8.09"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"6.86"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"7.50"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"7.90"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"8.17"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"7.88"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"11.13"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"10.41"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"9.24"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"5.84"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"5.99"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"6.66"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"6.44"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"6.34"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"6.21"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"8.02"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"9.27"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"9.18"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"9.71"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"8.56"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"7.45"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"7.10"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"10.43"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"8.84"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"7.06"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"9.25"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"9.63"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"8.10"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"11.44"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"8.24"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"8.72"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"7.54"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"6.47"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"9.98"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"7.85"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"6.91"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"10.58"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"11.34"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"9.31"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"7.47"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"8.06"}]}]}]},{"type":"PRIMARY","title":"CFB in Pulse Oximetry- Part A","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":"2.22"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.03"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.42"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.90"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.02"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.42"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.23"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.46"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.08"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.64"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.50"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.02"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.83"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.97"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.02"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.38"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.91"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.17"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.28"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.31"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.79"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.86"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.70"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.44"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.33"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.59"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.90"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.36"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.28"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.63"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.96"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"3.69"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.73"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.82"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.09"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.87"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.28"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.29"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.42"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.68"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.76"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.61"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.72"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.82"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.36"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.72"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.73"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.56"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.34"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.87"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.61"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.59"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.37"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.03"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.34"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.09"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.52"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.84"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.79"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.27"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.38"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.28"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.92"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.50"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.45"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.99"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.33"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.94"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.59"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.76"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.27"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.77"}]}]}]},{"type":"PRIMARY","title":"CFB in Electrocardiogram (ECG) Mean Heart Rate - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats/min","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":"11.85"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"6.77"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"6.78"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"7.65"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"8.89"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"5.53"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"5.31"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"10.71"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"4.50"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"7.11"}]}]},{"title":"Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"5.37"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"8.76"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"6.03"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"6.78"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"4.17"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"9.32"}]}]}]},{"type":"PRIMARY","title":"CFB in Aggregate PR Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"milliseconds (msec)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"158.0","lowerLimit":"122","upperLimit":"228"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-16","upperLimit":"26"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-9","upperLimit":"17"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-20","upperLimit":"25"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","lowerLimit":"-26","upperLimit":"22"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-18","upperLimit":"13"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","lowerLimit":"-24","upperLimit":"17"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-32","upperLimit":"18"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","lowerLimit":"-18","upperLimit":"21"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","lowerLimit":"-25","upperLimit":"22"}]}]},{"title":"Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-30","upperLimit":"15"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-26","upperLimit":"14"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","lowerLimit":"-32","upperLimit":"19"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-18","upperLimit":"20"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","lowerLimit":"-24","upperLimit":"20"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","lowerLimit":"-34","upperLimit":"86"}]}]}]},{"type":"PRIMARY","title":"CFB in Aggregate RR Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"milliseconds (msec)","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"950.0","lowerLimit":"684","upperLimit":"1226"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-32.5","lowerLimit":"-298","upperLimit":"190"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-43.5","lowerLimit":"-298","upperLimit":"285"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-99.0","lowerLimit":"-263","upperLimit":"98"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-98.5","lowerLimit":"-376","upperLimit":"252"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-56.0","lowerLimit":"-143","upperLimit":"211"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-102.0","lowerLimit":"-276","upperLimit":"-30"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-133.0","lowerLimit":"-386","upperLimit":"182"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-65.0","lowerLimit":"-150","upperLimit":"84"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-63.0","lowerLimit":"-196","upperLimit":"36"}]}]},{"title":"Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-113.5","lowerLimit":"-228","upperLimit":"28"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-76.5","lowerLimit":"-420","upperLimit":"179"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-104.5","lowerLimit":"-226","upperLimit":"125"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-120.0","lowerLimit":"-344","upperLimit":"70"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","lowerLimit":"-118","upperLimit":"114"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-86.0","lowerLimit":"-189","upperLimit":"169"}]}]}]},{"type":"PRIMARY","title":"CFB in Aggregate QT Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"406.0","lowerLimit":"340","upperLimit":"445"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","lowerLimit":"-16","upperLimit":"64"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","lowerLimit":"-39","upperLimit":"39"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","lowerLimit":"-44","upperLimit":"66"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.5","lowerLimit":"-92","upperLimit":"84"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","lowerLimit":"-41","upperLimit":"22"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.0","lowerLimit":"-42","upperLimit":"24"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.0","lowerLimit":"-42","upperLimit":"18"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","lowerLimit":"-33","upperLimit":"30"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","lowerLimit":"-61","upperLimit":"9"}]}]},{"title":"Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","lowerLimit":"-35","upperLimit":"26"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","lowerLimit":"-48","upperLimit":"56"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","lowerLimit":"-50","upperLimit":"20"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","lowerLimit":"-50","upperLimit":"55"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-26","upperLimit":"32"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","lowerLimit":"-38","upperLimit":"20"}]}]}]},{"type":"PRIMARY","title":"CFB in Aggregate QRS Duration - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","lowerLimit":"76","upperLimit":"106"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-14","upperLimit":"8"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-5","upperLimit":"22"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-16","upperLimit":"18"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-20","upperLimit":"16"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-18","upperLimit":"16"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-14","upperLimit":"12"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-6","upperLimit":"8"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-16","upperLimit":"15"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-18","upperLimit":"12"}]}]},{"title":"Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-14","upperLimit":"21"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-16","upperLimit":"14"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-22","upperLimit":"14"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-12","upperLimit":"13"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-16","upperLimit":"18"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"-10","upperLimit":"12"}]}]}]},{"type":"PRIMARY","title":"CFB in Aggregate QTcF Interval - Part A","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"419.0","lowerLimit":"386","upperLimit":"435"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-21","upperLimit":"39"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-32","upperLimit":"33"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-29","upperLimit":"53"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"-85","upperLimit":"50"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","lowerLimit":"-65","upperLimit":"28"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-19","upperLimit":"31"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","lowerLimit":"-23","upperLimit":"26"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"-20","upperLimit":"24"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"-38","upperLimit":"32"}]}]},{"title":"Day 6 (SAGE-217): 12 hours postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","lowerLimit":"-14","upperLimit":"34"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-16","upperLimit":"32"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-35","upperLimit":"23"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","lowerLimit":"-17","upperLimit":"46"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-19","upperLimit":"37"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","lowerLimit":"-52","upperLimit":"35"}]}]}]},{"type":"PRIMARY","title":"CFB in Stanford Sleepiness Scale (SSS) Score - Part A","description":"The SSS was a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of one to seven, where the lowest score of 'one' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of 'seven' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. A negative change from baseline indicated less sleepiness. A positive change from baseline indicated more sleepiness. Baseline is the last measurement taken before the first dose of study drug. L/C indicated levodopa/carbidopa. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa). Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.56"}]}]},{"title":"CFB at Day 1 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.26"}]}]},{"title":"CFB at Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.26"}]}]},{"title":"CFB at Day 1 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.52"}]}]},{"title":"CFB at Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.65"}]}]},{"title":"CFB at Day 1 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.76"}]}]},{"title":"CFB at Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.39"}]}]},{"title":"CFB at Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.58"}]}]},{"title":"CFB at Day 1 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.90"}]}]},{"title":"CFB at Day 1 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.85"}]}]},{"title":"CFB at Day 2 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.74"}]}]},{"title":"CFB at Day 2 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.73"}]}]},{"title":"CFB at Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.58"}]}]},{"title":"CFB at Day 2 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.22"}]}]},{"title":"CFB at Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.91"}]}]},{"title":"CFB at Day 2 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.20"}]}]},{"title":"CFB at Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.96"}]}]},{"title":"CFB at Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.47"}]}]},{"title":"CFB at Day 2 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.94"}]}]},{"title":"CFB at Day 2 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.75"}]}]},{"title":"CFB at Day 3 (L/C): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.91"}]}]},{"title":"CFB at Day 3 (L/C): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.68"}]}]},{"title":"CFB at Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.91"}]}]},{"title":"CFB at Day 3 (L/C): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.07"}]}]},{"title":"CFB at Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.15"}]}]},{"title":"CFB at Day 3 (L/C): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.90"}]}]},{"title":"CFB at Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.85"}]}]},{"title":"CFB at Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.01"}]}]},{"title":"CFB at Day 3 (L/C): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.18"}]}]},{"title":"CFB at Day 3 (L/C): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.79"}]}]},{"title":"CFB at Day 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.61"}]}]},{"title":"CFB at Day 4 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.28"}]}]},{"title":"CFB at Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"2.03"}]}]},{"title":"CFB at Day 4 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.57"}]}]},{"title":"CFB at Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.63"}]}]},{"title":"CFB at Day 4 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.01"}]}]},{"title":"CFB at Day 4 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.93"}]}]},{"title":"CFB at Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.43"}]}]},{"title":"CFB at Day 4 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.43"}]}]},{"title":"CFB at Day 4 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.82"}]}]},{"title":"CFB at Day 5 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.47"}]}]},{"title":"CFB at Day 5 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"1.79"}]}]},{"title":"CFB at Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.68"}]}]},{"title":"CFB at Day 5 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.38"}]}]},{"title":"CFB at Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.42"}]}]},{"title":"CFB at Day 5 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.96"}]}]},{"title":"CFB at Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.47"}]}]},{"title":"CFB at Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.43"}]}]},{"title":"CFB at Day 5 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.94"}]}]},{"title":"CFB at Day 5 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.07"}]}]},{"title":"CFB at Day 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.73"}]}]},{"title":"CFB at Day 6 (SAGE-217): 1 Hour Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.74"}]}]},{"title":"CFB at Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.85"}]}]},{"title":"CFB at Day 6 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.21"}]}]},{"title":"CFB at Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.94"}]}]},{"title":"CFB at Day 6 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.30"}]}]},{"title":"CFB at Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.91"}]}]},{"title":"CFB at Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.89"}]}]},{"title":"CFB at Day 6 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.74"}]}]},{"title":"CFB at Day 6 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.19"}]}]},{"title":"CFB at Day 7 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.58"}]}]},{"title":"CFB at Day 7 (SAGE-217): 1 hour postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.66"}]}]},{"title":"CFB at Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.38"}]}]},{"title":"CFB at Day 7 (SAGE-217): 3 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.14"}]}]},{"title":"CFB at Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.33"}]}]},{"title":"CFB at Day 7 (SAGE-217): 6 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.86"}]}]},{"title":"CFB at Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.97"}]}]},{"title":"CFB at Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.83"}]}]},{"title":"CFB at Day 7 (SAGE-217): 14 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.01"}]}]},{"title":"CFB at Day 7 (SAGE-217): 16 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.01"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.62"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.59"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item - Part A","description":"The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included \"yes\" or \"no\"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part A of the study.","populationDescription":"The safety population included all participants who were administered study drug (SAGE-217 or levodopa).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Suicidal Ideation: Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Suicidal Ideation: Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Suicidal Behavior: Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Suicidal Behavior: Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"CFB in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II/III Score - Part B","description":"The modified MDS-UPDRS included 4 scales, with various subscales. Each item was rated from 0 (normal) to 4 (severe). The scales were Part I: nonmotor experiences of daily living (13 items); Part II: motor experiences of daily living (13 items); Part III: motor examination (33 scores based on 18 items \\[several with right, left or other body distribution scores\\]); and Part IV: motor complications (6 items). The Part II/III tremor score was calculated as the sum of 5 individual tremor item scores from Part II and Part III. The total score range for Part II/III is 0 to 44. Lower scores represent less symptom severity and higher scores represent more symptom severity. Baseline is the last measurement taken before the first dose of study drug. A negative change from baseline indicates an improvement in symptom severity. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":"3.75"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"4.52"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"5.15"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"5.45"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"4.60"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"4.51"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"5.39"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"5.53"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"5.02"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"7.81"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"5.71"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"6.93"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"5.02"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"4.63"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"4.34"}]}]}]},{"type":"SECONDARY","title":"MDS-UPDRS Part III Total Score - Part A","description":"Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores indicate less symptom severity. The analysis was performed in participants included in Part A of the study.","populationDescription":"The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Days 1 to 7 (2, 4, 8, and 12 hours postdose), Day 8 and Day 14","groups":[{"id":"OG000","title":"Part A: Antiparkinsonian Agent(s) Followed by SAGE-217","description":"Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"title":"Day 1 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":"9.34"}]}]},{"title":"Day 1 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":"10.53"}]}]},{"title":"Day 1 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"10.83"}]}]},{"title":"Day 1 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"9.71"}]}]},{"title":"Day 2 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":"9.15"}]}]},{"title":"Day 2 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":"9.65"}]}]},{"title":"Day 2 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"11.37"}]}]},{"title":"Day 2 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":"11.07"}]}]},{"title":"Day 3 (L/C): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":"10.95"}]}]},{"title":"Day 3 (L/C): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"10.95"}]}]},{"title":"Day 3 (L/C): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":"10.76"}]}]},{"title":"Day 3 (L/C): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":"11.29"}]}]},{"title":"Day 4 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":"14.57"}]}]},{"title":"Day 4 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"12.84"}]}]},{"title":"Day 4 (SAGE-217):8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.4","spread":"11.65"}]}]},{"title":"Day 4 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":"13.19"}]}]},{"title":"Day 5 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"12.76"}]}]},{"title":"Day 5 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"12.69"}]}]},{"title":"Day 5 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":"12.02"}]}]},{"title":"Day 5 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":"12.15"}]}]},{"title":"Day 6 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":"11.97"}]}]},{"title":"Day 6 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":"9.66"}]}]},{"title":"Day 6 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":"12.81"}]}]},{"title":"Day 6 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":"11.19"}]}]},{"title":"Day 7 (SAGE-217): 2 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":"12.55"}]}]},{"title":"Day 7 (SAGE-217): 4 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":"11.92"}]}]},{"title":"Day 7 (SAGE-217): 8 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":"11.73"}]}]},{"title":"Day 7 (SAGE-217): 12 Hours Postdose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":"11.03"}]}]},{"title":"Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":"10.54"}]}]},{"title":"Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":"13.00"}]}]}]},{"type":"SECONDARY","title":"CFB in the MDS-UPDRS Part III Total Score - Part B","description":"Part III of the MDS-UPDRS assessed 18 motor categories, some of which included right and left measurements: speech, facial expression, kinetic tremor of hands, rest tremor amplitude, postural tremor of hands, rigidity of neck and 4 extremities, finger taps, hand movement, pronation/supination, toe tapping, constancy of rest tremor, leg agility, arising from chair, posture, gait, freezing of gait, postural stability, global spontaneity of movement. Part III total score was calculated as the sum of the individual item scores from these categories. Each item was rated from 0 (normal) to 4 (severe). The total score range for Part III is 0 to 132. Lower scores represent less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":"12.00"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"8.74"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"9.90"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-11.6","spread":"12.83"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"7.87"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":"10.51"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"9.39"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"12.25"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-14.8","spread":"10.30"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-14.5","spread":"15.52"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-18.1","spread":"10.10"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-14.8","spread":"11.81"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-19.5","spread":"9.30"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-18.6","spread":"9.51"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-14.5","spread":"10.54"}]}]}]},{"type":"SECONDARY","title":"CFB in the MDS-UPDRS Part I Total Score - Part B","description":"Part I of the MDS-UPDRS assessed 13 nonmotor experiences of daily living categories. Part I total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 7 (12 hours postdose), Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"6.33"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"6.54"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"6.05"}]}]}]},{"type":"SECONDARY","title":"CFB in the MDS-UPDRS Part II Total Score - Part B","description":"Part II of the MDS-UPDRS assessed 13 categories of motor experiences of daily living: speech, salivation and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor, getting out of bed, car, or deep chair, walking and balance, and freezing. The Part II total score was calculated as the sum of the individual item scores from these categories. The total score range for Part II is 0 to 52. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Days 1 to 6 (12 and 23 hours postdose), Day 7 (12 hours postdose), Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"8.26"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"3.46"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"3.73"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"5.17"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"4.92"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"5.48"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"4.20"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"6.33"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"5.43"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"5.71"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"4.90"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"5.05"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 23 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"5.40"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"4.34"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"5.02"}]}]}]},{"type":"SECONDARY","title":"CFB in the MDS-UPDRS Part I-IV Total Score - Part B","description":"The MDS-UPDRS assesses nonmotor experiences, motor experiences, motor skills, and motor complication categories. The MDS-UPDRS Part I-IV total score was calculated as the sum of the individual item scores from these categories. The total score range for Part I-IV is 0 to 260. Lower scores indicate less symptom severity. A negative change from baseline indicates an improvement in symptom severity. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The efficacy population included all participants in the safety population who received at least one dose of study drug and had at least one postdose MDS-UPDRS evaluation.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 7 (12 hours postdose), Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":"24.01"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-30.0","spread":"17.71"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-24.1","spread":"20.75"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With TEAEs - Part B","description":"An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was as an AE that occurred after the first administration of study drug. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."},{"id":"OG001","title":"Part B: Follow-up","description":"Participants received antiparkinsonian agent(s) at normally prescribed dosing schedule for Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With TEAEs, Graded by Severity - Part B","description":"Severity was assessed according to the following scale: mild (awareness of sign or symptom, but easily tolerated); moderate (discomfort sufficient to cause interference with normal activities); severe (incapacitating, with inability to perform normal activities). The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."},{"id":"OG001","title":"Part B: Follow-up","description":"Participants received antiparkinsonian agent(s) at normally prescribed dosing schedule for Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"}]}],"classes":[{"title":"Mild","categories":[{"measurements":[{"groupId":"OG000","value":"42.9"},{"groupId":"OG001","value":"0"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"CFB in Basophils - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.074"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.089"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.058"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.061"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.055"}]}]}]},{"type":"SECONDARY","title":"CFB in Basophils to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.39"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.97"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.00"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.47"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"CFB in Eosinophils - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.058"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.065"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.083"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.114"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.058"}]}]}]},{"type":"SECONDARY","title":"CFB in Eosinophils to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.04"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.20"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.95"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.06"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"CFB in Erythrocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^12 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":"0.335"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.798"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.186"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.208"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.101"}]}]}]},{"type":"SECONDARY","title":"CFB in Hematocrit - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"L/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.436","spread":"0.0357"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.0775"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.011","spread":"0.0182"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.0268"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.002","spread":"0.0119"}]}]}]},{"type":"SECONDARY","title":"CFB in Hemoglobin - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"140.1","spread":"14.22"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"20.90"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"5.32"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"6.03"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"4.48"}]}]}]},{"type":"SECONDARY","title":"CFB in Leukocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"6.47","spread":"1.322"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"2.677"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"1.370"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.935"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"1.287"}]}]}]},{"type":"SECONDARY","title":"CFB in Lymphocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"0.549"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.857"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"0.386"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.283"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.373"}]}]}]},{"type":"SECONDARY","title":"CFB in Lymphocytes to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":"6.31"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"6.15"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"5.34"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"5.57"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"5.73"}]}]}]},{"type":"SECONDARY","title":"CFB in Monocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.096"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.194"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.083"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.133"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.110"}]}]}]},{"type":"SECONDARY","title":"CFB in Monocytes to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"1.55"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.68"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.49"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.74"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.07"}]}]}]},{"type":"SECONDARY","title":"CFB in Neutrophils - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.23","spread":"0.957"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"1.842"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.136"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.902"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"1.153"}]}]}]},{"type":"SECONDARY","title":"CFB in Neutrophils to Leukocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":"5.28"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"7.50"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"6.64"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"6.69"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"6.69"}]}]}]},{"type":"SECONDARY","title":"CFB in Platelets - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"189.2","spread":"37.72"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":"67.75"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"13.64"}]}]},{"title":"CFB at Day 8 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"20.01"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"19.58"}]}]}]},{"type":"SECONDARY","title":"CFB in Reticulocytes - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":"19.27"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"11.35"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"19.61"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"15.55"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"20.99"}]}]}]},{"type":"SECONDARY","title":"CFB in Reticulocytes to Erythrocytes Ratio (%) - Part B","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets, reticulocytes and reticulocytes to erythrocytes ratio. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study. The blood cell differential (ratio) data are presented as SI unit, percentage (%).","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"0.417"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.250"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.410"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.334"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.486"}]}]}]},{"type":"SECONDARY","title":"CFB in Activated Partial Thromboplastin Time - Part B","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.05","lowerLimit":"22.0","upperLimit":"27.5"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","lowerLimit":"-2.1","upperLimit":"0.2"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-1.7","upperLimit":"1.2"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","lowerLimit":"-1.6","upperLimit":"0.5"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","lowerLimit":"-1.4","upperLimit":"1.7"}]}]}]},{"type":"SECONDARY","title":"CFB in Prothrombin International Normalized Ratio - Part B","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"0.043"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.045"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.051"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.041"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.036"}]}]}]},{"type":"SECONDARY","title":"CFB in Prothrombin Time - Part B","description":"Coagulation measures included activated partial thromboplastin time, prothrombin international normalized ratio and prothrombin time. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.60","lowerLimit":"9.6","upperLimit":"11.0"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","lowerLimit":"-0.8","upperLimit":"0.6"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","lowerLimit":"-0.5","upperLimit":"0.5"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","lowerLimit":"-0.4","upperLimit":"0.5"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","lowerLimit":"-0.3","upperLimit":"0.6"}]}]}]},{"type":"SECONDARY","title":"CFB in Alanine Aminotransferase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"6.66"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"3.17"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"5.42"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"3.79"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"3.70"}]}]}]},{"type":"SECONDARY","title":"CFB in Albumin - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":"2.75"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.40"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.65"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"1.45"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.86"}]}]}]},{"type":"SECONDARY","title":"CFB in Alkaline Phosphatase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":"22.05"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"7.55"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.23"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"8.85"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"8.69"}]}]}]},{"type":"SECONDARY","title":"CFB in Aspartate Aminotransferase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":"10.59"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"10.63"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"10.93"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"11.51"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"10.12"}]}]}]},{"type":"SECONDARY","title":"CFB in Bicarbonate - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":"1.74"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.90"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.06"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.23"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"CFB in Bilirubin - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.306","spread":"2.4050"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.993","spread":"2.4320"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.795","spread":"2.0751"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.122","spread":"2.4611"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.366","spread":"3.0129"}]}]}]},{"type":"SECONDARY","title":"CFB in Calcium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.340","spread":"0.0796"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.0859"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"0.0599"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.0638"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.027","spread":"0.0709"}]}]}]},{"type":"SECONDARY","title":"CFB in Chloride - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"102.1","spread":"2.03"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.38"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.53"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.10"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.36"}]}]}]},{"type":"SECONDARY","title":"CFB in Creatinine - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.381","spread":"23.1753"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.345","spread":"17.8035"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.084","spread":"12.3449"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.968","spread":"8.0917"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.253","spread":"10.0339"}]}]}]},{"type":"SECONDARY","title":"CFB in Lipase - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.2","spread":"16.74"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":"9.64"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"16.88"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"6.08"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"9.30"}]}]}]},{"type":"SECONDARY","title":"CFB in Magnesium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.873","spread":"0.0489"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.014","spread":"0.0536"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.009","spread":"0.0401"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.018","spread":"0.0448"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.012","spread":"0.0591"}]}]}]},{"type":"SECONDARY","title":"CFB in Phosphate - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.091","spread":"0.1489"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.161","spread":"0.1496"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.180","spread":"0.1386"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.042","spread":"0.1775"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","spread":"0.1939"}]}]}]},{"type":"SECONDARY","title":"CFB in Potassium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.57","spread":"0.292"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.319"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.264"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.295"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.268"}]}]}]},{"type":"SECONDARY","title":"CFB in Protein - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":"5.40"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.75"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"3.00"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.68"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.00"}]}]}]},{"type":"SECONDARY","title":"CFB in Sodium - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"141.8","spread":"1.97"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.78"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.46"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.21"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.00"}]}]}]},{"type":"SECONDARY","title":"CFB in Urate - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.291","spread":"0.0748"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.001","spread":"0.0252"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":"0.0360"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.0254"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.007","spread":"0.0319"}]}]}]},{"type":"SECONDARY","title":"CFB in Urea Nitrogen - Part B","description":"Clinical chemistry measures included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium, chloride, creatinine, lipase, magnesium, phosphate, potassium, protein, sodium, urate and urea nitrogen. Baseline is the last measurement taken before the first dose of the study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.993","spread":"1.7667"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.142","spread":"1.9554"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.275","spread":"1.7917"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.663","spread":"1.9345"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.153","spread":"1.2580"}]}]}]},{"type":"SECONDARY","title":"CFB in Specific Gravity - Part B","description":"Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.018","spread":"0.0061"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","spread":"0.0038"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":"0.0053"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.004","spread":"0.0077"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.0063"}]}]}]},{"type":"SECONDARY","title":"CFB in pH - Part B","description":"Urinalysis measures included specific gravity and pH. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug. Number analyzed = Number of participants with data available at the specific time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pH","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":"0.924"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"1.103"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"1.085"}]}]},{"title":"CFB at Day 8 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":"0.984"}]}]},{"title":"CFB at Day 14 (Follow-up)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.820"}]}]}]},{"type":"SECONDARY","title":"CFB in Temperature - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"degrees C","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"36.56","spread":"0.306"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.199"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.316"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.316"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.370"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.375"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.310"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.380"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.485"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.327"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.282"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.386"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.451"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.408"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.358"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.336"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.418"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.423"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.562"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.512"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.240"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.266"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.289"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.363"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.477"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.348"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.352"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.415"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.291"}]}]}]},{"type":"SECONDARY","title":"CFB in Heart Rate - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats/min","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":"9.25"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"7.82"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"7.78"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"15.35"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"7.14"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"12.44"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"11.94"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"11.08"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"9.02"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"7.67"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"7.95"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"10.36"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"8.16"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"9.41"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"8.31"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"9.65"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"8.97"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"10.61"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"9.08"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"9.12"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"8.61"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"7.08"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"6.13"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"11.29"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"8.42"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"8.76"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"8.93"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"6.83"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"8.34"}]}]}]},{"type":"SECONDARY","title":"CFB in Respiratory Rate - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"breaths/min","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"1.91"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.99"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.98"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.31"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.07"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.09"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.50"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.58"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.79"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.74"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.03"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.50"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.36"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.55"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.86"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.87"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.45"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.98"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"2.38"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.79"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.74"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.64"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.99"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.78"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.02"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.39"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.40"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.65"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.90"}]}]}]},{"type":"SECONDARY","title":"CFB in Supine Systolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"131.7","spread":"16.50"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"9.15"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"7.60"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"13.81"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"18.20"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"14.61"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"16.11"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"18.57"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.35"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"10.64"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"13.21"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"22.03"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"16.26"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"14.22"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"14.21"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"18.07"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"14.67"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"15.54"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"18.79"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"11.82"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"17.18"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"18.68"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"18.48"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"15.90"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"12.63"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"12.33"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"11.94"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"13.98"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"15.55"}]}]}]},{"type":"SECONDARY","title":"CFB in Standing Systolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"127.8","spread":"14.89"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"10.51"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"8.41"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"7.68"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"15.96"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"14.03"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"15.49"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"13.50"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"11.77"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"11.56"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"11.21"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"17.29"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"12.68"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"18.50"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"11.25"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"13.38"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"8.26"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"12.07"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"14.59"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"10.01"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"8.80"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"11.05"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"10.25"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"11.05"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"9.01"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"10.60"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"13.18"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"12.79"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"14.50"}]}]}]},{"type":"SECONDARY","title":"CFB in Supine Diastolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":"7.49"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"7.13"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"7.20"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"7.23"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"10.00"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"9.23"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"9.75"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"9.07"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"8.54"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"7.39"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"12.21"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"11.15"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"9.24"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"8.29"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"8.18"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"9.76"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"9.05"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"9.92"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"9.44"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"9.00"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"9.24"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"9.49"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"9.15"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"9.74"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"9.16"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"10.50"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"8.50"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"8.93"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"8.30"}]}]}]},{"type":"SECONDARY","title":"CFB in Standing Diastolic Blood Pressure - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":"6.99"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"6.04"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"6.32"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"7.17"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"7.18"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"5.11"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"7.69"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"8.64"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"8.60"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"9.08"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"7.44"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"7.79"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"7.53"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"9.77"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"8.69"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"9.18"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"8.93"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"7.91"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"8.51"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"10.03"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"7.74"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"8.35"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"7.65"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"8.27"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"9.21"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"8.86"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"8.14"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"8.59"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"9.21"}]}]}]},{"type":"SECONDARY","title":"CFB in Pulse Oximetry - Part B","description":"Vital sign measures included temperature, heart rate, respiratory rate, supine systolic blood pressure, standing systolic blood pressure, supine diastolic blood pressure, standing diastolic blood pressure and pulse oximetry. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":"1.51"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.60"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"2.08"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.86"}]}]},{"title":"CFB at Dose 2 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.77"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.64"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.73"}]}]},{"title":"CFB at Dose 2 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.38"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.51"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.02"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.87"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"2.15"}]}]},{"title":"CFB at Dose 4 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.69"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.01"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.46"}]}]},{"title":"CFB at Dose 4 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.09"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.34"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.91"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.66"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.55"}]}]},{"title":"CFB at Dose 6 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.63"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.33"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.33"}]}]},{"title":"CFB at Dose 6 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.64"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.25"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.65"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 2 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.71"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.79"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.91"}]}]}]},{"type":"SECONDARY","title":"CFB in ECG Mean Heart Rate - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats/min","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":"10.24"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"5.55"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"7.81"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"6.19"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"5.03"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"9.88"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"6.28"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"7.82"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"9.39"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"6.81"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"6.97"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"6.35"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"8.57"}]}]}]},{"type":"SECONDARY","title":"CFB in Aggregate PR Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"174.0","lowerLimit":"141","upperLimit":"203"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"-20","upperLimit":"96"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-24","upperLimit":"17"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-29","upperLimit":"8"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-33","upperLimit":"8"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"-27","upperLimit":"20"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"-28","upperLimit":"46"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-19","upperLimit":"12"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-22","upperLimit":"22"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-17","upperLimit":"18"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-36","upperLimit":"10"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-26","upperLimit":"27"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","lowerLimit":"-31","upperLimit":"7"}]}]}]},{"type":"SECONDARY","title":"CFB in Aggregate RR Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"823.0","lowerLimit":"683","upperLimit":"1239"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","lowerLimit":"-93","upperLimit":"142"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"67.5","lowerLimit":"-68","upperLimit":"366"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-32.5","lowerLimit":"-85","upperLimit":"141"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","lowerLimit":"-140","upperLimit":"143"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"-164","upperLimit":"231"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-23.5","lowerLimit":"-132","upperLimit":"99"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-24.5","lowerLimit":"-148","upperLimit":"96"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"-185","upperLimit":"304"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","lowerLimit":"-80","upperLimit":"212"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-26.0","lowerLimit":"-76","upperLimit":"180"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"16.5","lowerLimit":"-148","upperLimit":"74"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"66.0","lowerLimit":"-76","upperLimit":"397"}]}]}]},{"type":"SECONDARY","title":"CFB in Aggregate QT Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"374.0","lowerLimit":"361","upperLimit":"442"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"-41","upperLimit":"36"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"10.0","lowerLimit":"-20","upperLimit":"70"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-21","upperLimit":"32"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"-34","upperLimit":"31"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-52","upperLimit":"31"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-35","upperLimit":"17"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","lowerLimit":"-37","upperLimit":"25"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"-45","upperLimit":"41"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","lowerLimit":"-23","upperLimit":"21"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"-32","upperLimit":"32"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"-30","upperLimit":"21"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"-19","upperLimit":"57"}]}]}]},{"type":"SECONDARY","title":"CFB in Aggregate QRS Duration - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"99.5","lowerLimit":"76","upperLimit":"153"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-9","upperLimit":"12"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-8","upperLimit":"16"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-11","upperLimit":"9"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-12","upperLimit":"10"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-14","upperLimit":"6"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-10","upperLimit":"16"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"-5","upperLimit":"11"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","lowerLimit":"-12","upperLimit":"6"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-5","upperLimit":"238"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-10","upperLimit":"6"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-11","upperLimit":"6"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"-11","upperLimit":"11"}]}]}]},{"type":"SECONDARY","title":"CFB in Aggregate QTcF Interval - Part B","description":"ECG measures included ECG mean heart rate, aggregate PR interval, aggregate RR interval, aggregate QT interval, aggregate QRS duration and aggregate QTcF interval. Baseline is the last measurement taken before the first dose of study drug. Doses 1 to 7 were given on Days 1 to 7, respectively. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"msec","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"407.0","lowerLimit":"384","upperLimit":"432"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"-35","upperLimit":"54"}]}]},{"title":"CFB at Dose 1 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","lowerLimit":"-34","upperLimit":"60"}]}]},{"title":"CFB at Dose 3 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-11","upperLimit":"28"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"-18","upperLimit":"29"}]}]},{"title":"CFB at Dose 3 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","lowerLimit":"-37","upperLimit":"12"}]}]},{"title":"CFB at Dose 5 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"-19","upperLimit":"19"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-19","upperLimit":"22"}]}]},{"title":"CFB at Dose 5 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"-27","upperLimit":"17"}]}]},{"title":"CFB at Dose 7 (SAGE-217): Predose","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","lowerLimit":"-16","upperLimit":"29"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 1 Hour Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-25","upperLimit":"20"}]}]},{"title":"CFB at Dose 7 (SAGE-217): 12 Hours Postdose","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-11","upperLimit":"17"}]}]},{"title":"CFB at Day 14 (Follow-up)","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"-10","upperLimit":"21"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of 'Yes' to Any C-SSRS Suicidal Ideation or Suicidal Behavior Item - Part B","description":"The C-SSRS scale consisted of a baseline evaluation (at screening) that assessed the lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and a postbaseline evaluation that focused on suicidality since the last study visit. The C-SSRS included \"yes\" or \"no\"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for the severity of ideation, if present (from 1 to 5, with 5 being the most severe). The C-SSRS SI items involved wish to be dead, non-specific active suicidal thoughts, active SI with any methods, active SI with some intent and active SI with a specific plan. The C-SSRS SB items involved actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior, suicidal behavior and suicide. The analysis was performed in participants included in Part B of the study.","populationDescription":"The safety population included all participants who were administered study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 to Day 14","groups":[{"id":"OG000","title":"Part B: Antiparkinsonian Agent(s) + SAGE-217","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"}]}],"classes":[{"title":"Suicidal Ideation: Wish to be Dead: Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"14.3"}]}]},{"title":"Suicidal Ideation: Wish to be Dead: Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Suicidal Behavior: Pre-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Suicidal Behavior: Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Part A: Up to 14 days; Part B: Up to 14 days","description":"The safety population included all participants who were administered study drug \\[SAGE-217 or levodopa (Part A); or SAGE-217 or antiparkinsonian agent(s) (Part B)\\]. Number of participants at risk is number of participants in the safety population that remained in the study during each period.","eventGroups":[{"id":"EG000","title":"Part A: Antiparkinsonian Agent(s) Day 1 to Day 3","description":"Participants received levodopa as antiparkinsonian agents at the normally prescribed dosing schedule, orally for Days 1 to 3.","deathsNumAffected":0,"deathsNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":4,"otherNumAtRisk":15},{"id":"EG001","title":"Part A: SAGE-217 Day 4 to Day 7","description":"Participants received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. If the initial dose was not tolerated, doses could be reduced to 10 or 20 mg per day.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":14,"otherNumAtRisk":14},{"id":"EG002","title":"Part A: Follow-up","description":"Participants resumed levodopa as antiparkinsonian agents at the normally prescribed dosing schedule for Days 8 to 14.","deathsNumAffected":0,"deathsNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":2,"otherNumAtRisk":15},{"id":"EG003","title":"Part B: SAGE-217 Dose 1 to Dose 7","description":"Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":8,"otherNumAtRisk":14},{"id":"EG004","title":"Part B: Follow-up","description":"Participants received antiparkinsonian agent(s) at normally prescribed dosing schedule for Days 8 to 14.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":0,"otherNumAtRisk":14}],"otherEvents":[{"term":"Sedation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":15},{"groupId":"EG001","numAffected":10,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":2,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":6,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":2,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":4,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":2,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Myoclonus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":3,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Cognitive Disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Dyskinesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Migraine with Aura","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Parkinson's Disease","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":3,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Abdominal Distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":1,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Faeces soft","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":1,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Salivary Hypersecretion","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Feeling drunk","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":4,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Orthostatic Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":2,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Photophobia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Lipase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":1,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Limb Discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Panic Attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":0,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":1,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]},{"term":"Dermatitis Contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":15},{"groupId":"EG001","numAffected":1,"numAtRisk":14},{"groupId":"EG002","numAffected":0,"numAtRisk":15},{"groupId":"EG003","numAffected":0,"numAtRisk":14},{"groupId":"EG004","numAffected":0,"numAtRisk":14}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication."},"pointOfContact":{"title":"US Biogen Clinical Trial Center","organization":"Biogen","email":"clinicaltrials@biogen.com","phone":"866-633-4636"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-06-08","uploadDate":"2020-09-17T20:30","filename":"Prot_001.pdf","size":6637928},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: Version 2","date":"2017-08-02","uploadDate":"2020-09-17T19:41","filename":"SAP_000.pdf","size":11235706},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan: Version 1","date":"2017-02-06","uploadDate":"2020-09-17T20:39","filename":"SAP_002.pdf","size":9738893}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D010300","term":"Parkinson Disease"}],"ancestors":[{"id":"D020734","term":"Parkinsonian Disorders"},{"id":"D001480","term":"Basal Ganglia Diseases"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D009069","term":"Movement Disorders"},{"id":"D000080874","term":"Synucleinopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000634505","term":"zuranolone"},{"id":"D007980","term":"Levodopa"}],"ancestors":[{"id":"D004295","term":"Dihydroxyphenylalanine"},{"id":"D002395","term":"Catecholamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D002396","term":"Catechols"},{"id":"D010636","term":"Phenols"},{"id":"D001555","term":"Benzene Derivatives"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D010649","term":"Phenylalanine"},{"id":"D024322","term":"Amino Acids, Aromatic"},{"id":"D000598","term":"Amino Acids, Cyclic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014443","term":"Tyrosine"}]}},"hasResults":true}